Increasing Eligibility to Transplant Through the Selective Cytopheretic Device: A Review of Case Reports Across Multiple Clinical Conditions
Open Access
- 16 May 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (6) , e1627
Abstract
A stable, minimum physiological health status is required for patients to qualify for transplant or artificial organ support eligibility to ensure the recipient has enough reserve to survive the perioperative transplant period. Herein, we present a novel strategy to stabilize and improve patient clinical status through extracorporeal immunomodulation of systemic hyperinflammation with impact on multiple organ systems to increase eligibility and feasibility for transplant/device implantation. This involves treatment with the selective cytopheretic device (SCD), a cell-directed extracorporeal therapy shown to adhere and immunomodulate activated neutrophils and monocytes toward resolution of systemic inflammation. In this overview, we describe a case series of successful transition of pediatric and adult patients with multiorgan failure to successful transplant/device implantation procedures by treatment with the SCD in the following clinical situations: pediatric hemophagocytic lymphohistiocytosis, and adult hepatorenal and cardiorenal syndromes. Application of the SCD in these cases may represent a novel paradigm in increasing clinical eligibility of patients to successful transplant outcomes. ExportKeywords
Funding Information
- National Institute of Health
- National Institute of Health
This publication has 36 references indexed in Scilit:
- Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failurePediatric Nephrology, 2022
- Regenerative Medicine and Immunomodulatory Therapy: Insights From the Kidney, Heart, Brain, and LungKidney International Reports, 2018
- Immunomodulatory Device Therapy in a Pediatric Patient With Acute Kidney Injury and Multiorgan DysfunctionKidney International Reports, 2017
- Clinical Course of acute‐on‐chronic liver failure syndrome and effects on prognosisHepatology, 2015
- Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart FailureJAMA, 2007
- Hemophagocytic syndromesBlood Reviews, 2007
- Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategiesCardiovascular Research, 2007
- Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart FailureJAMA, 2007
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJAMA, 2007
- Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injuryCardiovascular Research, 2004